AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$LFST

Paunovich Vukasin sold $541K of LFST

Paunovich Vukasin (Chief Technology Officer) sold 42,067 shares of LifeStance Health Group, Inc. (LFST) at $12.87 ($0.54M total) on 2026-09-02.

Original reporting
SEC EDGAR · Paunovich Vukasin
Published Sep 4, 2026, 8:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 9:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$LFST
Neutral
low confidence
Mentioned
$LFST
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LFSTNeutralLow
01

Why it matters

The sale is modest and unlikely to move the stock significantly, but traders monitoring insider activity may adjust short-term positions.

02

Market read

Primary insider sale with limited material impact; low trading relevance.

03

What to watch

Potential upcoming corporate actions or compensation restructuring not disclosed.

Relevance 5/10Novelty 4/10Timing: filed Sep 4 2026

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$LFSTNeutralLow confidence
Context

CTO Paunovich Vukasin sold 42,067 shares of LifeStance Health for $541,402.

Expected impact

Minor downward pressure, likely limited to short-term volatility.

Evidence & confidence

The transaction size is modest relative to market cap and does not constitute a material change in ownership.

Market effects

Sector

No significant sector impact; health services sector unchanged.

Regional

Limited to U.S. market participants tracking insider activity.

Global

Negligible global relevance.

Counterpoint

What could challenge this read

Sale could be unrelated to confidence; may reflect personal financial planning.

Key entities

  • Company
    LifeStance Health Group, Inc.

    Public mental health services provider (ticker LFST).

  • Individual
    Paunovich Vukasin

    Chief Technology Officer of LifeStance Health.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LFST insider trading history →

Related articles

$LFSTMed

BMO raises Lifestance Health stock price target on strong results

BMO Capital raised its price target on Lifestance Health (LFST) to $16.00, citing strong Q3 results. Revenue beat estimates by 5.6%, and EBITDA exceeded by 23.6%. The company raised its full-year outlook, but expects a sequential EBITDA decline due to reinvestment. LFST trades at $13.43 with a $5.1B market cap. The company also announced Q3 2026 earnings, surpassing expectations with a 25% revenue increase.

investing.com
$LFSTMed

What LifeStance Health Group (LFST) Said on Its Q3 Earnings Call

LifeStance Health Group (LFST) forecasted Q4 revenue of $446M-$466M and adjusted EBITDA of $56M-$64M. The company expects a 1-2% reduction in 2027 revenue growth due to a new electronic health record system. LifeStance expanded specialty services, including TMS and SPRAVATO, and plans to continue acquisitions and center openings. Management expects specialty services revenue to reach $70M this year, up from $50M in 2025.

finance.yahoo.com
$LFSTMed

LifeStance Health Group Inc (LFST) (Q3 2026) Earnings Call Highlights: Revenue Jumps 25%

LifeStance Health (LFST) reported 25% revenue growth in Q3 2026. The company expects EHR implementation to reduce 2027 revenue growth by 1-2% and cost $20-30M. Clinician retention is stable, but new clinician retention is low. Q4 adjusted EBITDA guidance suggests a sequential decline due to planned investments. Specialty services, including Spravato, are growing but face variable payer reimbursement. Management remains optimistic about long-term margin expansion and clinician growth.

finance.yahoo.com
$LFSTHighAI 8/10

LifeStance (LFST) Q3 2026 Earnings Call Transcript

LifeStance (LFST) reported Q3 2026 revenue growth of 25% to $456M, driven by increased visit volumes and higher revenue per visit. The company expanded its clinician base by 11% and opened 8 new centers. It also raised full-year revenue guidance to $1.741B-$1.761B. LifeStance highlighted strong results in specialty services for treatment-resistant depression and plans to invest in strategic priorities. The company expects temporary revenue growth impact in 2027 due to EHR implementation.

finance.yahoo.com
$LFSTMed

LifeStance Health: Q3 Earnings Snapshot

LifeStance Health Group Inc. (LFST) reported Q3 net income of $22.4M, or 6 cents per share, beating estimates. Revenue was $455.9M, also exceeding forecasts. The company expects Q4 revenue of $446M-$466M and full-year revenue of $1.74B-$1.76B.

finance.yahoo.com